New treatments for rhabdomyosarcoma: The importance of target practice

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 595-597

  Barr, Frederic G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYBRID PROTEIN; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA;

APOPTOSIS; CANCER INHIBITION; CANCER REGRESSION; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 2P; CHROMOSOME TRANSLOCATION; COPY NUMBER VARIATION; DOWN REGULATION; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE FUSION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; IN VIVO STUDY; LUNG SMALL CELL CANCER; MEDICAL PRACTICE; MEDULLOBLASTOMA; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NEGATIVE FEEDBACK; NEUROBLASTOMA; NOTE; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; ONCOGENE CDK4; ONCOGENE MIR 17 HG; ONCOGENE MYCN; ONCOGENE PAX3 FOXO1; ONCOGENE PAX7 FOXO1; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETINOBLASTOMA; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; UPREGULATION;

EID: 84856557865     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2832     Document Type: Note

References (12)

1. Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, et al. Antitumor activity of sustained N-Myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 2012;18:796-807.
2. Barr FG. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001;20:5736-46. (Pubitemid 32928111)
3. Barr FG, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, et al. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer 2009;48:661-72.
4. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, et al. Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Clin Cancer Res 2011;17:1463-73.
5. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204: 179-87. (Pubitemid 38167721)
6. Thomas WD, Raif A, Hansford L, Marshall G. N-myc transcription molecule and oncoprotein. Int J Biochem Cell Biol 2004;36:771-5. (Pubitemid 38299392)
7. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 2005;23:880-8. (Pubitemid 46224189)
8. Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar andembryonal rhabdomyosarcoma: focus onMYCN as a biologically relevant target. Genes Chromosomes Cancer 2008;47:510-20. (Pubitemid 351657186)
9. Tonelli R, Purgato S, Camerin C, Fronza R, Bologna F, Alboresi S, et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis. Mol Cancer Ther 2005;4:779-86. (Pubitemid 40767122)
10. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010;70:6497-508.
11. Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 2008;68:9583-8.
12. Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol 2009;175:2600-8.